Pacira BioSciences (PCRX) Cash & Current Investments (2010 - 2026)

Pacira BioSciences' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $202.2 million for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 59.04% year-over-year to $202.2 million; the TTM figure through Mar 2026 stood at $202.2 million (down 59.04% YoY), while the FY2025 annual figure was $238.4 million, down 50.8% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $202.2 million, down from $238.4 million in the prior quarter.
• The five-year high for Cash & Current Investments was $493.6 million in Q1 2025, with the low at $174.0 million in Q1 2023.
• The 5-year median for Cash & Current Investments is $316.4 million (2022), against an average of $328.8 million.
• The sharpest annual moves came in 2023 and 2024: Cash & Current Investments sank 61.52% in 2023, then soared 92.96% in 2024.
• Pacira BioSciences' Cash & Current Investments stood at $288.7 million in 2022, then fell by 3.49% to $278.6 million in 2023, then jumped by 73.96% to $484.6 million in 2024, then sank by 50.8% to $238.4 million in 2025, then decreased by 15.2% to $202.2 million in 2026.
• Business Quant data shows PCRX's Cash & Current Investments at $202.2 million in Q1 2026, $238.4 million in Q4 2025, and $246.3 million in Q3 2025.